NKGen Biotech, Inc.

NKGen Biotech, Inc. (Nasdaq: NKGN) is a clinical-stage biopharmaceutical company developing natural killer cell-based immunotherapies, with lead programs targeting Alzheimer's disease and oncology indications. The company became publicly traded through a de-SPAC merger with Graf Acquisition Corp. IV, a blank-check vehicle sponsored by Graf Acquisition LLC that completed its IPO in 2022. The business combination closed in October 2023, with NKGen filing an 8-K on October 5, 2023, to report the completion of the transaction and the company's debut on Nasdaq under the ticker NKGN. NKGen operates within the cell therapy segment of the broader biotech and life sciences sector. Sign up at SpacDesk for comprehensive data, filings, and analytics on NKGN and the full SPAC universe.